Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company's
application for Orfadin oral suspension has been submitted to the US Food and
Drug Administration (FDA). This new dosage form has been developed to facilitate
the ease and accuracy of administration for Orfadin in paediatric patients as
well as to increase convenience for patients and their caregivers.
---
About Orfadin
Orfadin is used for the treatment of hereditary tyrosinemia type 1 (HT-1), a
rare genetic disorder which can cause liver failure, kidney dysfunction and
neurological problems.
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
For more information - not for publication
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson@sobi.com jorgen.winroth@sobi.com
[HUG#1738708]
